The latest price target for bioAffinity Technologies (NASDAQ:BIAF) was reported by Maxim Group on April 1, 2025. The analyst firm set a price target for $0.00 expecting BIAF to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for bioAffinity Technologies (NASDAQ:BIAF) was provided by Maxim Group, and bioAffinity Technologies downgraded their hold rating.

There is no last upgrade for bioAffinity Technologies

The last downgrade for bioAffinity Technologies Inc happened on April 1, 2025 when Maxim Group changed their price target from N/A to N/A for bioAffinity Technologies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bioAffinity Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bioAffinity Technologies was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.

While ratings are subjective and will change, the latest bioAffinity Technologies (BIAF) rating was a downgraded with a price target of $0.00 to $0.00. The current price bioAffinity Technologies (BIAF) is trading at is $0.43, which is out of the analyst’s predicted range.